Related references
Note: Only part of the references are listed.Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
Kathryn Davidson et al.
CELL DEATH & DISEASE (2021)
Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer
Jia Bian et al.
CELLS (2020)
Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC)
Wentian Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Noritaka Tanaka et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells
Dong Hoon Kang et al.
NATURE COMMUNICATIONS (2017)
Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade
Chia-Sheng Yen et al.
SCIENTIFIC REPORTS (2016)
Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study
Ronac Mamtani et al.
PLOS MEDICINE (2016)
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
Sara Costa-Cabral et al.
PLOS ONE (2016)
Rac1 augments Wnt signaling by stimulating β-catenin-lymphoid enhancer factor-1 complex assembly independent of β-catenin nuclear import
Cara Jamieson et al.
JOURNAL OF CELL SCIENCE (2015)
Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies
Yanqiong Liu et al.
CANCER CAUSES & CONTROL (2014)
Exploiting APC Function as a Novel Cancer Therapy
Alyssa C. Lesko et al.
CURRENT DRUG TARGETS (2014)
BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs
Brian Leibowitz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade
Hang-Lung Chang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Statins and Colorectal Cancer
Paul Lochhead et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Survivin - biology and potential as a therapeutic target in oncology
Chun Hei Antonio Cheung et al.
ONCOTARGETS AND THERAPY (2013)
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
Michael Steckel et al.
CELL RESEARCH (2012)
A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells
G. Zhu et al.
ONCOGENE (2012)
Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin
Ki-Eun Hwang et al.
INVESTIGATIONAL NEW DRUGS (2011)
Effect of statin therapy on colorectal cancer
Marc Bardou et al.
GUT (2010)
The armadillo repeat domain of Apc suppresses intestinal tumorigenesis
Richard C. Crist et al.
MAMMALIAN GENOME (2010)
Mouse Models of Colon Cancer
Makoto Mark Taketo et al.
GASTROENTEROLOGY (2009)
Mutated K-rasAsp12 promotes tumourigenesis in ApcMin mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways
Feijun Luo et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih-Min A. Huang et al.
NATURE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Targeted Constitutive Mutation in the Apc Tumor Suppressor Gene Underlies Mammary But Not Intestinal Tumorigenesis
Claudia Gaspar et al.
PLOS GENETICS (2009)
Rac1 activation controls nuclear localization of β-catenin during canonical Wnt signaling
Ximei Wu et al.
CELL (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor-induced apoptosis in cancer
Reiko Kaneko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Colorectal cancer and genetic alterations in the Wnt pathway
S. Segditsas et al.
ONCOGENE (2006)
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCmin mice
Malisetty V. Swamy et al.
CANCER RESEARCH (2006)
Statins and the risk of colorectal cancer
JN Poynter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
The mechanism of PAK activation - Autophosphorylation events in both regulatory and kinase domains control activity
C Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Can APC:: mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis?: Experience from 680 FAP families
W Friedl et al.
GUT (2001)
Biology of the adenomatous polyposis coli tumor suppressor
KH Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
